Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.
-
Upload
penelope-chambers -
Category
Documents
-
view
216 -
download
1
Transcript of Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.
![Page 1: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/1.jpg)
Bone Marrow Failure/ Bone Marrow Failure/ Aplastic AnemiaAplastic Anemia
Bone Marrow Failure/ Bone Marrow Failure/ Aplastic AnemiaAplastic Anemia
Dr. MERVAT A.HESHAMDr. MERVAT A.HESHAM
20082008
![Page 2: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/2.jpg)
What is Aplastic Anemia?
Aplastic Anemia is a bone marrow failure disease.
Bone marrow is a Factory of Blood Cells
Red Blood Cell
White Blood Cell
Platelets
Help to save a Life www.aaaoi.org
![Page 3: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/3.jpg)
Aplastic Anemia patients
•Aplastic Anemia patients have decreased amounts of:- Red Blood Cells
-White Blood Cells -Platelets
Help to save a Life www.aaaoi.org
![Page 4: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/4.jpg)
Functions of Blood Cells
Red Blood CellsCarry oxygen to all body organsWhite Blood CellsFight infection and keep you healthyPlateletsHelp control bleeding
Help to save a Life www.aaaoi.org
![Page 5: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/5.jpg)
Symptoms
Low Red Blood CellFatigue, Headache, Inability to ConcentrateLow White Blood CellViral Infections, Bacterial InfectionsLow PlateletsEasy Bruising, Nosebleeds, Petichiae
Help to save a Life www.aaaoi.org
![Page 6: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/6.jpg)
DEFINITIONA disorder of the hemtopoietic system characterized by:Bone marrow - marked reduction of all 3 cell lines
Peripheral blood - pancytopenia
![Page 7: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/7.jpg)
PATHOGENESISStem cell failure resulting from:
1-An acquired intrinsic stem cell defect
2-An environmental cause Immune mechanisms
Growth factor deficiency
Defects in the microenvironment
![Page 8: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/8.jpg)
EpidemiologyIncidence: 5-10:106 per year
Age: 15 –30 years > 60 years
Sex: M = F
![Page 9: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/9.jpg)
Etiology
Hereditary
1-Schwacman – Diamond
2-Fanconi’s anemia syndrome
3-Dyskeratosis congenita
Acquired1-Idiopathic
2 -Drugs: dose relatedidiosyncratic
3-Radiation 4-Chemicals
5-Viruses6-Pregnancy
7-PNH8-Disorders of immune
system
![Page 10: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/10.jpg)
Clinical manifestations
Insidious onsetManifestations caused by pancytopeniaAnemia - weakness, fatigueThrombocytopenia – bleedingNeutropenia - infections
![Page 11: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/11.jpg)
Diagnosis
Peripheral blood*Pancytopenia
*Normocytic-normochromic anemia
*Low reticulocyte index
Bone marrow biopsy
*Empty fatty spaces
*Few hematopoietic cells
*Lymphocytes and plasma cells
![Page 12: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/12.jpg)
Bone Marrow FailureCongenital/ SyndromicAcquired
![Page 13: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/13.jpg)
Acquired Aplastic Acquired Aplastic AnemiaAnemia
Acquired Aplastic Acquired Aplastic AnemiaAnemia
![Page 14: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/14.jpg)
Acquired Aplastic Anemia
**Secondary
**Idiopathic
![Page 15: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/15.jpg)
Secondary AA1-Meds/ toxins
Chemo Chloramphenicol, benzene,
carbamazapine, indomethacin, cimetidine, sulfas, acetazolamide, lithium
2 -Radiation3-Viruses - EBV, HIV, parvo, hepatitis
![Page 16: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/16.jpg)
4-Paroxysmal Nocturnal Hemoglobinurea
5-Malnutrition6-Myelodysplastic syndromes
7-Thymoma
![Page 17: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/17.jpg)
PATHOPHYSIOLOGYDirect toxic injury to hematopoietic stem cells can be induced by exposure toionizing radiation, cytotoxic chemotherapy, or benzene. These agents can crosslinkDNA and induce DNA strand breaks leading to inhibition of DNA and RNA synthesis.
![Page 18: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/18.jpg)
2-Immune-mediated destruction of hematopoietic stem cells
--Direct killing of the stem cells has been hypothesized to occur via interations between Fas ligand expressed on the T-cells and Fas (CD95) present on the stem cells, which triggers programmed cell death (apoptosis) .
--T-lymphocytes also may suppress stem cell proliferation by elaborating soluble factors including interferon-γ.
![Page 19: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/19.jpg)
-T cells from aplastic anemia patients secrete IFN-ã and tumor necrosis factor (TNF).
-IFN-ã and TNF are potent inhibitors of both early and late hematopoietic progenitor cells.
-Both of these cytokines suppress hematopoiesis by their effects on the mitotic cycle and, more importantly, by the mechanism of cell killing .
-Activation of the Fas receptor on the hematopoietic stem cell by the Fas ligand present on the lymphocytes leads to apoptosis of the targeted hematopoietic progenitor
cells.
![Page 20: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/20.jpg)
*Cytotoxic T cells also secrete interleukin-2 (IL-2), which causes polyclonal expansion of the T cells.
*IFN-ã also induces the production of the toxic gas nitric oxide, diffusion of which causes additional toxic effects on the
hematopoietic progenitor cells .
![Page 21: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/21.jpg)
Young NEJM 1997
Suppress proliferation
with ligand, signals apoptosis
![Page 22: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/22.jpg)
![Page 23: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/23.jpg)
Idiopathic AA*70% or more of cases
Higher in SE AsiaM = F
![Page 24: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/24.jpg)
AA - Clinical **Symptoms are due to pancytopenia:
pallor, mucosal bleeding, ecchymoses, or petechiae and bacterial or fungal
infections.. **Hepatosplenomegaly and
lymphadenopathy do not occur; their presence suggestsan underlying leukemia.
**Hyperplastic gingivitis is also a symptom of aplastic anemia.
![Page 25: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/25.jpg)
AA - LabsNo RBC = pale, tachycardicNo plt = bruising, bleedingNo WBC = infectionRetic < 1%Plt < 20,000ANC < 500
![Page 26: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/26.jpg)
AA - LabsMarrow : < 25% cellularity
![Page 27: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/27.jpg)
![Page 28: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/28.jpg)
AA - Evaluation*CBC w/ diff and retic
*Bone marrow
*Send DEB (Fanconi’s test)*Send Hep A, B, C, D titers HIV
*Test for PNH (CD55, CD59)*HLA typing
*Fetal hemoglobin*Liver and renal function chemistries
![Page 29: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/29.jpg)
*Quantitative immunoglobulins, C3,
C4, and complement. *Autoimmune disease evaluation:
Antinuclear antibody (ANA), total hemolytic complement (CH50), Coombs’ test.
*HLA typing: Patient and family done at the time of diagnosis of severe aplastic anemia to ensure a timely transplant.
![Page 30: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/30.jpg)
CLASSIFICATIONDesignationDesignationCriteriaCriteria
Peripheral bloodBM biopsy
Severe aplastic anemia
-2 / 3 values-Neutrophils > 500/L
-Platelets > 20,000/ ul--Reticulocyte index >
1%
-Marked hypocellular > 25% cellularity
-Moderate hypocellular >25-50%
-normal cellularity with >30% of remaining cell hematopoietic
Very severe aplastic anemia
As above but neutrophils > 200/LInfection present
![Page 31: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/31.jpg)
Treatment Options
Bone Marrow Transplant
GrowthHormones
Immune SuppressiveTherapy
Supportive Care
Help to save a Life www.aaaoi.org
![Page 32: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/32.jpg)
TREATMENT1-Withdrawal of the etiologic agent
2-Supportive treatmentBlood and platelet transfusion used with caution- sensitization (filtered)
3-Allogeneic BMT- Preferably from sibling
- Curative in 60-90% of patients- Applicable only for a third of patients
*Immunosuppression Cyclosporin + ATG
Corticosteroids High dose cyclophosphamide
*G-CSF/ GM-CSF/ EPO - maybe** Response rate 50-70% Occurs 2-3 months
post Rx.
![Page 33: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/33.jpg)
AANewer
*Mycophenolate mofetil (MMF) - cytotoxic to T cells
*Monoclonal Ab against IL-2 receptor which is present on activated lymphocytes
![Page 34: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/34.jpg)
AA - Outcomes
Age, Younger is betterBMT
<20 yr with a sib… 75%20 - 40 yr with a sib…60%
<20 yr unrelated BMT… 40%20 - 40 yr unrelated BMT…35%
Immunosuppression - 60 - 80%But for how long and consequences…
![Page 35: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/35.jpg)
Fanconi AnemiaFanconi AnemiaFanconi AnemiaFanconi Anemia
![Page 36: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/36.jpg)
History: Guido FanconiFanconi Anemia (Fanconi pancytopenia syndrome): 1927 - 3 brothers with pancytopenia and physical abnormalities, “perniziosiforme”
Fanconi Syndrome (renal Fanconi syndrome): 1936 – Ricketts, growth retardation, proteinuria, glucosuria, and proximal renal tubular acidosis
Alter, FA101 (2006)
![Page 37: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/37.jpg)
Fanconi Anemia (FA)Rare (< 1/ 100,000 births)Autosomal recessiveMany physical featuresBut up to 20-25% will have no physical findings
Mean age at dx 7.8 yrs
![Page 38: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/38.jpg)
Autosomal Recessive Autosomal Recessive InheritanceInheritance
![Page 39: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/39.jpg)
FA- Clinical
Abnormality %of FA Patients
Skin60%
Short Stature57%
Upper Limb Abnl48%
Head/ Microcephaly27%
Renal23%
Dev. Delay13%
None Reported20%
Short Stature Only1%
Skin Only3%
![Page 40: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/40.jpg)
![Page 41: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/41.jpg)
![Page 42: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/42.jpg)
Progressive bone marrow failure Most common etiology of inherited bone marrow failureOthers include dykeratosis congenita, amegakaryocytic thrombocytopenia, Schwachman-Diamond syndrome
Increased risk of MDS and AML (15,000x)Many have monosomy 7, or duplication of 1q (Auerbach et al., Cancer Genet Cytogenet 1991)
Clinical Features
![Page 43: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/43.jpg)
Clinical FeaturesIncreased risk of solid tumor formation (hepatic, esophageal, oropharyngeal, vulvar)Average age at diagnosis is 23*
Cumulative incidence ~30% by age 45**
*Shimamura et al., Gene Reviews 2002 (genetests.org)**Alter et al. Blood 2003
![Page 44: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/44.jpg)
FA - geneticsIdentification of subtypes (compliment groups)A, B, C, D1, D2, E, F, GIdentical clinicallySub-units of a common protein/ common pathway
Protein modifies FANCD2FANCD2 interacts with BRCA1 and 2BRCA1 and 2 needed for DNA repair
![Page 45: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/45.jpg)
![Page 46: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/46.jpg)
![Page 47: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/47.jpg)
PATHOPHYSIOLOGYDNA damage activates a complex consisting of Fanconi proteins A, C, G, and F. This in turn leads to the modification of the FANCD2 protein. This protein interacts, for example, with the breast cancer susceptibility gene BRCA1.
![Page 48: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/48.jpg)
*Fanconi anemia cells are characterized by hypersensitivity to chromosomal breakage as well as hypersensitivity to G2/M cell cycle arrest induced by DNA cross-linking agents.
* In addition there is sensitivity to oxygen-free radicals and to ionizingradiation.
![Page 49: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/49.jpg)
Diagnosis*-Pts. with congenital abnormalities are
often diagnosed as neonates/infants*Others may be diagnosed when
hematological problems occur*Median age of onset of pancytopenia is 7
Usually normal CBC at birth*First develop macrocytosis, then
thrombocytopenia, and eventually neutropenia
![Page 50: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/50.jpg)
DiagnosisBased on chromosomal hypersensitivity to cross-linking agentsChromosome fragility test: Mitomycin C (MMC) or diepoxybutane (DEB) added to lymphoctyes – increases the number of chromosome breaks and radial structuresVery specific for FA, regardless of severity of diseaseCan do chromosome breakage analysis on amniotic cells, chorionic villus cells or fetal blood
![Page 51: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/51.jpg)
![Page 52: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/52.jpg)
FA cells were treated with mitomycin C and harvested in metaphase. Typical abnormalities include radial formation (green circle) and chromosome breaks (red arrows).
![Page 53: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/53.jpg)
Initial managementRefer for genetic counselingTesting of siblingsRenal ultrasound, hearing test, eye examEndocrine evaluation if evidence of growth failure (check growth hormone levels, TSH)Referral to hand surgeon for radial ray defects Bone marrow biopsy
![Page 54: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/54.jpg)
Management•Bone marrow failure
–Transfusions–Androgens (e.g. oral oxymethalone) – can improve
blood counts in 50% of pts.•Side effects: Masculinization, acne, hyperactivity,
premature closure of epiphyses, liver toxicity, hepatic adenomas
–Growth factors (G-CSF, CM-CSF) – should not be used in patients with clonal cytogenetic abnormalities
–Bone marrow transplantation•FA cells are very sensitive to radiation and alkylating
agents – can use greatly reduced doses •2-yr. survival 70% for allo;* 20-40% for MUD**
*Guardiola et al. Bone Marrow Transplant 1998;**MacMillan et al., Br J Haematol 2000
![Page 55: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/55.jpg)
Management - Gene therapy
*Goal is to permanently correct hematological manifestations by transducing hematopoietic progenitor cells with a vector containing the deficient gene
*Knockout mice with FANCC using retroviral vectors - phenotypic correction (Gush et al., Blood 2000)
*Knockout mice with FANCA and FANCC using lentiviral vectors – more promising (integrates into the genome) (Galimi et al. Blood 2002)
![Page 56: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/56.jpg)
Other Congenital Marrow Failures
Dystkeratosis CongenitaRareDifferent modes of inheritanceEctodermal dysplasia
50% develop aplastic anemia in midteens
Schwachman-DiamondCartilage-Hair HypoplasiaFamilial Marrow Dysfunction
![Page 57: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/57.jpg)
Marrow Failure
Pearson’s syndromeSeckel’s syndromeAmegakaryocytic ThrombocytopeniaNoonan’s syndrome
![Page 58: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/58.jpg)
Marrow FailureSingle Cytopenias
-Pure Red Cell Aplasia (Diamond-Backfan)
-Congenital Neutropenia (Kostmann’s) -Thrombocytopenia with Absent
Radii
![Page 59: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/59.jpg)
![Page 60: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/60.jpg)
Definition
A syndrome characterized by
Normocytic normochromic anemia
Reticulocytopenia <1%
BM erythroblasts < 0.5%
Aplasia selective to erythroid cell line
only!
![Page 61: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/61.jpg)
EpidemiologyRelatively uncommonMay affect any age group but predominantly ofinfancy and childhood
M=F
No ethnic predisposition
Of autosomal dominant inheritance
![Page 62: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/62.jpg)
Etiology & Pathogenesis
Congenital hypoplastic
anemia
)Diamond-Blackfan syndrome(
Acquired PRCA
Primary
Secondary
![Page 63: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/63.jpg)
PrimaryPrimaryAutoimmunePreleukemicIdiopathic
SecondarySecondaryThymoma
Hematologic malignanciesSolid tumors
InfectionsChronic hemolytic anemiasCollagen vascular diseases
PregnancySevere renal failure
Severe nutritional deficienciesDrugs & chemicals
Miscellaneous
Acquired PRCA
![Page 64: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/64.jpg)
![Page 65: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/65.jpg)
Mechanisms of Immunologic Inhibition
Antibodies directed againstErythropoietin
Erythroblasts?
Cellular inhibitionInhibitory T cellsNK cells
![Page 66: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/66.jpg)
Pure red cell aplasia
IgG inhibitors T cell inhibition Parvovirus
Erythropoietin Epo Responsive cells
![Page 67: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/67.jpg)
Clinical Manifestations
Symptoms of anemia*The median age at presentation of anemia
is 2 months and the median age at diagnosis of DBA is 3 months.
*Physical anomalies, excluding short stature*No hepatosplenomegaly.
*Malignant potential
In patients with long-standing PRCA – transfusional hemosiderosis
![Page 68: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/68.jpg)
Laboratory Evaluation
Diagnostic criteria:
--Normochromic, usually macrocytic anemia, relative to patient’s age and occasionally
normocytic anemia developing in early childhood
--Reticulocytopenia
--Normal or only slightly decreased granulocyte count
--Normal or slightly increased platelet count
Supportive criteria:
-Typical physical abnormalities
-Increased fetal hemoglobin
-Increased erythrocyte adenosine deaminase (eADA) activity
![Page 69: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/69.jpg)
BM*Absence of erythroblasts <1% on BM
)absence of normoblasts, in some cases with relative increase in proerythroblasts or normal number of proerythroblasts with a
maturation arrest .(
*normal myeloid and megakaryocytic series.
* Usually – normal karyotype, except for preleukemic cases
![Page 70: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/70.jpg)
![Page 71: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/71.jpg)
TreatmentCongenital Hypoplastic
Anemia
Corticosteroids
AlloBMT
IL-3 –experimental
Patients refractory to all treatments – regular transfusions & desferioxamine
![Page 72: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/72.jpg)
Treatment Acquired PRCA
-Discontinuation of all drugs-R/O infections
-If parvovirus suspected – high dose IgG-In the presence of thymoma – thymectomy
![Page 73: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/73.jpg)
-In 30-40% erythropoiesis remits within 4-8 weeks
-Non-responding pts. – should be treated as primary acquired PRCA
-Thymectomy in the absence of thymoma is not recommended
-If an underlying disease – treat the disease
![Page 74: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/74.jpg)
Treatment Acquired PRCA
For primary or secondary PRCA not responding to treatment of underlying
disease:PrednisoneCyclophosphamide / azathioprineCyclosporineATGHigh dose IgGPlasmapheresisSplenectomyRituximab
![Page 75: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/75.jpg)
THANK YOU
![Page 76: Bone Marrow Failure/ Aplastic Anemia Dr. MERVAT A.HESHAM 2008.](https://reader035.fdocuments.us/reader035/viewer/2022062515/56649ccc5503460f949958fc/html5/thumbnails/76.jpg)